ArticleslgStudy

chemistry

Palovarotene

Palovarotene is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Palovarotene rather than just read about it. In short: Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist.

Palovarotene — main illustration
Palovarotene — illustration

Key takeaways

  • Palovarotene belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Palovarotene to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Palovarotene from memory before moving on to harder problems.

Reference excerpt

Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist. It is taken by mouth. It was approved for medical use in Canada in June 2022, and in the United States in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Palovarotene is indicated for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). A one-year trial did not demonstrate a significant benefit on lung density in moderate-to-severe emphysema secondary to severe α(1)-antitrypsin deficiency. In 2011, animal studies demonstrated that RARγ agonists, including palovarotene, blocked new bone formation in both an injury-induced mouse model of heterotopic ossification (HO) and a genetically modified biological mouse model of fibrodysplasia ossificans progressiva containing a continuously active ACVR1/ALK2 receptor in a dose-dependent manner. A 2016 study demonstrated that palovarotene also inhibited spontaneous heterotopic ossification, maintained limb mobility and functioning, and restored skeletal growth in fibrodysplasia ossificans progressiva mouse models.

Society and culture

Legal status Palovarotene is being developed by Ipsen Biopharmaceuticals and was granted priority review and orphan drug designations by the United States Food and Drug Administration (FDA) for the treatment of fibrodysplasia ossificans progressiva and orphan medicinal product designation by the European Medicines Agency (EMA) in 2014. Phase II clinical studies failed to show a significant change in heterotopic bone volume, the main outcome measure, but prompted further investigation in a phase III clinical trial. In December 2022, the FDA declined to approve palovarotene for the fibrodysplasia ossificans progressiva without additional clinical trial data. In January 2023, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for palovarotene for the treatment of fibrodysplasia ossificans progressiva. In May 2023, the European Medicines Agency confirmed its recommendation to refuse marketing authorization for Sohonos.

Research

Phase II Clementia submitted a new drug application for palovarotene for the treatment of fibrodysplasia ossificans progressiva after observing positive phase II results.

Phase III In December 2019, Ipsen issued a partial clinical hold for people under the age of 14, due to reports of early fusion of growth plates. Ipsen acquired Clementia in 2019.

References

External links Clinical trial number NCT03312634 for "An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)" at ClinicalTrials.gov

Illustrations

Palovarotene illustration

Worked examples

Example 1 — a first encounter with Palovarotene

Start with the simplest possible case. Write down what Palovarotene claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Palovarotene before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Palovarotene ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Palovarotene

In research
Palovarotene appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Palovarotene in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Palovarotene is common in secondary-school and first-year university syllabi. It links to neighbouring topics Benzoic acids, Orphan drugs, Pyrazoles, so understanding it makes those chapters shorter.
In everyday life
Look for Palovarotene outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Palovarotene” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Palovarotene in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Palovarotene means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Palovarotene out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Palovarotene in simple terms?

Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist.

Why does Palovarotene matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Palovarotene?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Palovarotene.

Tags

  • Benzoic acids
  • Orphan drugs
  • Pyrazoles
  • Retinoids
  • Tetralins

Keep exploring